Drugs (selected) in clinical development designed to produce acute and/or enduring therapeutic effects in anxiety disorders. Depicted are also novel drug-assisted psychotherapeutic approaches utilizing neuroplasticity/cognition enhancing effects of drugs.
AVN-101: (CD-008-0045 licenced as AVIANDR in Russia) antagonist at 5-HT2A, 2C, 6 and 7 receptors, adrenergic 2A, 2B and 2C receptors and histamine H1 receptors; BNC210: α7-nAChR negative allosteric modulator (NAM); CBD: cannabidiol; ITI-1284: deuterated form of lumateperone, targets 5-HT2A, D2 receptors and SERT (serotonin transporter); LSD: lysergic acid diethylamide; MDMA: 3,4-Methylendioxy-N-methylamphetamin; PAMs: positive allosteric modulators (PAM) of the GABA-A receptor; SEP-363856: 5-HT1A receptor and TAAR1 (trace amine-associated receptor 1) agonist.
Related content
Suicidal ideation is far more common than attempts in people with anxiety or depression, especially with comorbid disorders and severe depression.
Anxiety disorders in Europe carry substantial costs, with PTSD and panic disorder leading, followed by social anxiety, GAD, and agoraphobia.